Shire CEO Moves On to Galderma
Flemming Ornskov, MD, MPH, former Shire CEO before the Takeda buyout, takes the helm at Galderma. As the new CEO of Nestlé’s skin health offshoot, Dr. Ornskov will lead the aesthetics, prescription, and dermatological consumer care areas and build the company’s presence in the U.S. and China as it prepares for global expansion.
“The management and team at Nestlé Skin Health have done an excellent job creating a high-growth, leading dermatology business,” Dr. Ornskov said in a statement. “I believe that Galderma, as a newly focused pureplay dermatology business, has outstanding prospects built on its existing quality portfolio, team, and rich innovative pipeline. I look forward to working with the talented Galderma team to further build on its success to date.”
Prior to his time at Shire, Dr. Ornskov served in high-level executive positions at Bayer, Bausch & Lomb Inc., and Novartis.
Beam Gains Biologics Veteran
Beam, the biotechnology company developing precision genetic medicines through base editing, appoints Brian Riley as Vice President of Technical Operations. Riley brings 20 years of experience in manufacturing modalities covering drug substance, drug product, and packaging, as well as global multi-site leadership.
“I am tremendously excited to welcome Brian to our growing team,” John Evans, CEO of Beam, said in a statement. “Brian’s leadership will be invaluable to Beam as we progress our pipeline of base editing programs, which represents a potential new class of genetic medicines that can offer an important new treatment option for patients suffering from serious diseases.”
Riley joins Beam from Catalent Pharma Solutions, where he managed five biologics plants across North America and Europe. He will now help the company continue development of novel precision genetic medicine.
The leading global agency promoted veterans Lynnette Hunter to Executive Vice President, Director of Client Services, and Jeanine Koch to Executive Vice President, Director of Project Management. Hunter and Koch are now a part of the firm’s Senior Leadership Team, a five-person committee that advises on key business and policy decisions. Hunter managed some of the agency’s largest accounts and helped bring important products to market. She will now be responsible for account management, account planning, engagement strategy, media, and clinical information. Koch is trusted to expand AbelsonTaylor’s innovative approach to project management. Her teams identify effective ways of moving projects from concept to completion, positioning AbelsonTaylor to navigate a changing healthcare landscape.
A leader in the bundled payments/COE space, Carrum Health appoints Dan Nardi as Chief Operating Officer. Nardi previously led digital health startup Livongo as it scaled up from 13 employees to 600 strong. He will now use his 20 years of experience to scale the business and run all internal operations.
Dan Levengood has been added to the agency’s project delivery team as Vice President as the team takes aim for aggressive growth. Levengood says one of his main objectives is to foster the team’s sense of craft and rigor, encouraging novel thinking and innovation. With experience in PR, experiential marketing, data science, CRM, and traditional advertising, Levengood has a unique ability to look at problems from multiple angles and organize teams accordingly.
The immuno-oncology company announces Christopher Haqq MD, PhD, will become its new Executive Vice President, Head of Research and Development, and Chief Medical Officer. Dr. Haqq has years of experience leading oncology clinical trials, working with government regulatory agencies, and filing for investigational and breakthrough drugs. Prior to Elicio, Dr. Haqq was Chief Medical officer at Atara Biotherapeutics.
Eli Lilly and Company
Following Enrique Conterno’s retirement, Mike Mason will take over as Senior Vice President of Lilly and President of Lilly Diabetes and Lilly USA. Mason has been with the company for 30 years. He is currently overseeing Lilly’s connected care business, which leverages technology to enhance insulin delivery. Mason plans to continue this work while furthering Lilly’s portfolio.
Harrison and Star
The leading HCP-focused healthcare agency within Omnicom Health Group announced Adam Hessel as its new EVP, Executive Creative Director. Hessel successfully rebranded Harrison and Star to reflect a new creative vision. As Executive Creative Director, he will be responsible for building the agency into a powerhouse, elevating the creative profile of some of the healthcare industry’s top brands.
Former CDM CEO, Kyle Barich, has moved into medical cannabis, taking over as Holistic Industries’ new Chief Marketing Officer. He is charged with helping the company build individual brands of dispensaries and medical cannabis for a broad spectrum of medical marijuana users. Barich will first expand the cannabis company’s marketing team in order to innovate packaging, social media, and brand development.
Christopher Lee, PhD, joins the company focused on developing therapies that modulate historically undruggable targets, as its VP, Program Management. Dr. Lee spent 19 years at Gilead, where he supported teams working across early- and later-stage clinical testing. Now he will play a critical role in setting up a program management function at Kronos across both its San Mateo and Cambridge offices.
The San Francisco-based company focused on turning genetic insights into new medicines, gains Jonathan Lim, MD, as a dedicated board member. As Founder and Managing Partner at City Hill Ventures, Dr. Lim is a veteran in the founding, funding, and leading of biotechnology startups. His knowledge and expertise is expected to assist Maze as it continues to grow.
McCann Health Echo
Jill Beene is appointed President, McCann Health Echo, a full-service advertising agency solely focused on healthcare professionals and their patients. Beene is an expert at helping pharmaceutical brands benefit from customer insight, most recently serving as a leader at H4B Catapult, part of Havas Health and You. Beene is known to have a genuine interest in people, and a strong desire to make the customer point of view heard.
Barbara S. Fox, PhD, is taking charge of Massachusetts-based Rheos Medicines. Previously, she worked on developing antibody-based treatments for cancer and immune-mediated diseases, and will now lead metabolism-tuning therapies research. She served as CEO of Tilos and led its acquisition by Merck this year.